[HTML][HTML] Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the …
Journal of Clinical Oncology, 2019•ncbi.nlm.nih.gov
PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen
therapies, including abiraterone or enzalutamide. Given that previous reports suggested that
circulating tumor cell (CTC) AR-V7 detection is a poor prognostic indicator for the clinical
efficacy of secondary hormone therapies, we conducted a prospective multicenter validation
study.
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen
therapies, including abiraterone or enzalutamide. Given that previous reports suggested that
circulating tumor cell (CTC) AR-V7 detection is a poor prognostic indicator for the clinical
efficacy of secondary hormone therapies, we conducted a prospective multicenter validation
study.
Abstract
PURPOSE
Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given that previous reports suggested that circulating tumor cell (CTC) AR-V7 detection is a poor prognostic indicator for the clinical efficacy of secondary hormone therapies, we conducted a prospective multicenter validation study.
ncbi.nlm.nih.gov
